Global medical technology company BTL Group has confirmed the successful resolution of multiple patent infringement proceedings against Lexter Microelectronic Engineering Systems SL, the manufacturer of the WonderFace device.
The settlement requires Lexter to cease manufacture, global marketing, distribution and use of facial treatment technologies that combine radiofrequency and electrical muscle stimulation in the same system — the core technology that BTL says is protected by its intellectual property.
The legal action, initiated by BTL in several jurisdictions to defend its proprietary EMFACE technology, has culminated in a settlement that effectively halts the WonderFace product and related disposables from the market.
In a statement, the company said the outcome reinforces its commitment to protecting its intellectual property and customer investments.
‘The global and definitive impact of this settlement testifies to our dedication to defending BTL’s intellectual property and protecting the investments of our customers,’ said Tomas Schwarz, CEO of the BTL Group.
BTL’s legal campaign against Lexter began in late 2025, when the company lodged patent infringement claims in the Unified Patent Court and other venues, alleging that WonderFace’s technology was too close to the patented design and functional integration of EMFACE. Earlier industry reporting noted that BTL sought to restrict WonderFace distribution across multiple European jurisdictions as part of its enforcement strategy.
Patent enforcement has played an increasingly visible role in the aesthetic technology sector, where device makers seek to protect developments in energy-based treatments amid a competitive device landscape.
